Natera (NASDAQ:NTRA) Price Target Raised to $235.00

Natera (NASDAQ:NTRA) had its target price boosted by Stephens from $197.00 to $235.00 in a research report released on Thursday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other equities research analysts also recently weighed in on NTRA. Wells Fargo & Company boosted their price target on shares of Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. increased their price target on Natera from $210.00 to $240.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Piper Sandler lifted their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Barclays increased their target price on Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Canaccord Genuity Group boosted their target price on Natera from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Fifteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $216.65.

Natera Stock Performance

NASDAQ NTRA opened at $204.28 on Thursday. The stock has a market capitalization of $28.19 billion, a P/E ratio of -89.21 and a beta of 1.75. Natera has a 52 week low of $125.38 and a 52 week high of $212.21. The stock has a fifty day moving average of $181.51 and a 200-day moving average of $165.65.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.26) EPS. Equities research analysts forecast that Natera will post -1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Rowan E. Chapman sold 2,750 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares in the company, valued at $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00. Following the sale, the insider directly owned 117,559 shares of the company’s stock, valued at $18,808,264.41. This represents a 2.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 223,336 shares of company stock valued at $42,990,633 over the last 90 days. 5.63% of the stock is owned by company insiders.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Jackson Hole Trust acquired a new position in shares of Natera during the first quarter worth about $29,000. Horizon Investments LLC acquired a new position in Natera during the 3rd quarter worth approximately $32,000. TCTC Holdings LLC grew its stake in shares of Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 106 shares during the last quarter. Finally, Hilltop National Bank bought a new stake in shares of Natera in the second quarter worth $33,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.